Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Did you know that calendars are not the same everywhere in the world? Different countries…
Jammu and Kashmir etched their name in history by winning the Ranji Trophy 2025-26 in…
Union Minister Sarbananda Sonowal inaugurated three key infrastructure projects on National Waterway-2 (NW-2) along the…
The Indian Air Force (IAF) displayed its combat power during Exercise Vayu Shakti 2026 at…
The Central Bank of the UAE has unveiled what it calls the world’s first sovereign…
India’s forex reserves dropped by $2.11 billion to $723.608 billion which are according to the latest…